Corporate GovernanceJun 23, 2026, 06:01 AM
Compass Therapeutics Amends Bylaws for Exclusive Jurisdiction
AI Summary
Compass Therapeutics, Inc.'s Board of Directors approved the adoption of Second Amended and Restated Bylaws, effective June 22, 2026. These new bylaws amend the existing ones to establish exclusive jurisdiction in the United States District Courts for the District of Delaware and District of Massachusetts for resolving any claims arising under the Securities Act of 1933. This update supersedes the company's previous bylaws dated July 17, 2020.
Key Highlights
- Compass Therapeutics' Board approved Second Amended and Restated Bylaws on June 22, 2026.
- The New Bylaws establish exclusive jurisdiction for claims under the Securities Act of 1933.
- Jurisdiction is set in the US District Courts for the District of Delaware and District of Massachusetts.
- The new bylaws replace the previous Amended and Restated Bylaws from July 17, 2020.
Price Impact
More from CMPX